Enanta Reports Q2 Revenue of $17.2M, Beating Consensus
Reports Q2 revenue $17.2M, consensus $17.09M. "Since the inception of our immunology portfolio targeting type 2 diseases, our team has worked diligently to advance highly selective inhibitors of KIT, STAT6 and MRGPRX2 designed to enable convenient oral dosing and best-in-class profiles," said Jay Luly, Ph.D., President and Chief Executive Officer of Enanta. "This quarter, we achieved a key milestone with dosing initiation in our Phase 1 trial of EDP-978, an oral KIT inhibitor in development for chronic urticaria. Along with advancing EDP-978 into the clinic, we remain on track to file an IND for EPS-3903, our oral STAT6 inhibitor, and to nominate an MRGPRX2 development candidate, in the second half of 2026. In parallel, we are continuing to conduct enabling activities for a pivotal study of zelicapavir in adults at high risk of serious complications from RSV infection and look forward to providing an update on the development path later this quarter. With a strong balance sheet and ongoing royalty revenues, we are well-positioned to execute on our strategy and to deliver multiple value-driving milestones over the coming year."
Trade with 70% Backtested Accuracy
Analyst Views on ENTA
About ENTA
About the author
Enanta Pharmaceuticals Initiates Phase 1 Trial of EDP-978 for Chronic Urticaria
- Trial Initiation: Enanta Pharmaceuticals has announced the dosing of the first participant in a Phase 1 clinical trial for EDP-978, an oral once-daily KIT inhibitor aimed at treating chronic urticaria and other mast cell-driven diseases, marking a significant step in advancing its immunology program into clinical development.
- Participant Recruitment: The trial is expected to enroll approximately 98 healthy adult volunteers aged 18 to 65 years to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EDP-978, providing critical data for future treatment options.
- Data Release Expectations: Enanta anticipates reporting topline data in Q4 2026, including effects on biomarkers such as serum tryptase, which will offer important insights into the activity of EDP-978 and address the unmet medical needs in chronic urticaria treatment.
- Market Potential: Chronic urticaria significantly impacts patients' quality of life, with many existing therapies proving ineffective; thus, the development of EDP-978 not only aims to fill this medical gap but also presents substantial market opportunities and potential revenue growth for Enanta.
Agios Pharmaceuticals (AGIO) Shares Surge 18.6% Following FDA Approval of Aqvesme
- FDA Approval: Agios Pharmaceuticals announced that its drug Aqvesme received FDA approval, becoming the only treatment for non-transfusion-dependent and transfusion-dependent alpha or beta-thalassemia, which is expected to significantly enhance its market competitiveness.
- Stock Price Rebound: Following the FDA approval announcement, AGIO's stock surged 18.6% to $29.17, with trading volume exceeding average levels, indicating strong investor confidence in the company's prospects.
- Earnings Outlook: Although the upcoming quarterly report is expected to show a loss of $1.96 per share, a 12.6% year-over-year decline, revenues are projected at $11.14 million, reflecting a 3.8% increase from the previous year, demonstrating resilience amid challenges.
- Market Attention: AGIO's consensus EPS estimate has remained unchanged over the past 30 days, and despite the stock's rise, investors should monitor future earnings estimate revisions to assess whether the stock can maintain its upward momentum.
JP Morgan Begins Coverage of Enanta Pharmaceuticals (ENTA) with Positive Outlook
JP Morgan Coverage Initiation: On November 14, 2025, JP Morgan began coverage of Enanta Pharmaceuticals (NasdaqGS:ENTA) with an "Overweight" recommendation, projecting a 62.04% upside based on an average one-year price target of $19.53/share.
Projected Revenue and EPS: Enanta Pharmaceuticals is expected to see a significant increase in annual revenue, projected at $834 million, which represents a 1,186.29% growth, alongside a projected non-GAAP EPS of 10.27.
Institutional Ownership Trends: There are currently 275 funds reporting positions in Enanta Pharmaceuticals, with a slight increase in ownership and a total of 20,591K shares held by institutions, reflecting a 1.16% rise over the last three months.
Shareholder Activity: Notable changes in shareholder positions include Janus Henderson Group increasing its stake by 111.20%, while Millennium Management reduced its holdings by 53.85%, indicating varied strategies among institutional investors.
Enanta Shares Climb Following J.P. Morgan's Overweight Rating on RSV Treatment
Stock Performance: Enanta Pharmaceuticals' shares rose after J.P. Morgan initiated coverage with an Overweight rating, highlighting the potential of their experimental RSV therapy, zelicapavir.
Analyst Projections: Analyst Anupam Rama set a price target of $17 per share, forecasting over $1.5 billion in peak global sales for zelicapavir, with significant contributions expected from the U.S. market.
Clinical Trial Success: The stock's surge followed positive mid-stage trial results for zelicapavir, which is designed for high-risk outpatient adults with acute RSV, indicating strong market potential.
Partnership Opportunities: Enanta is likely to seek partnerships for zelicapavir, which could lead to substantial non-dilutive financing, with peak net global revenue estimates exceeding $300 million.
Enanta Pharmaceuticals Unveils Latest Findings on Zelicapavir and EDP-323, Its N-Protein and L-Protein Inhibitors for Respiratory Syncytial Virus (RSV) Treatment, at IDWeek™ 2025
Zelicapavir's Efficacy in Pediatric Patients: New data presented at IDWeek™ 2025 indicates that zelicapavir significantly shortens the duration of RSV symptoms in children aged 28 days to 36 months, with a median resolution time of 6.99 days compared to 8.60 days for placebo.
EDP-323's Potential in Prophylaxis: EDP-323 has shown high effectiveness in preventing RSV infection when administered post-exposure, with a study revealing that none of the participants receiving EDP-323 became infected, compared to 26% in the placebo group.
Enanta Pharmaceuticals Completes Stock Offering
Public Offering Closure: Enanta Pharmaceuticals has successfully closed its public offering of approximately 7.48 million shares.
Financial Implications: The completion of this offering may impact the company's financial position and future growth strategies.
Enanta Pharmaceuticals Initiates Phase 1 Trial of EDP-978 for Chronic Urticaria
- Trial Initiation: Enanta Pharmaceuticals has announced the dosing of the first participant in a Phase 1 clinical trial for EDP-978, an oral once-daily KIT inhibitor aimed at treating chronic urticaria and other mast cell-driven diseases, marking a significant step in advancing its immunology program into clinical development.
- Participant Recruitment: The trial is expected to enroll approximately 98 healthy adult volunteers aged 18 to 65 years to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EDP-978, providing critical data for future treatment options.
- Data Release Expectations: Enanta anticipates reporting topline data in Q4 2026, including effects on biomarkers such as serum tryptase, which will offer important insights into the activity of EDP-978 and address the unmet medical needs in chronic urticaria treatment.
- Market Potential: Chronic urticaria significantly impacts patients' quality of life, with many existing therapies proving ineffective; thus, the development of EDP-978 not only aims to fill this medical gap but also presents substantial market opportunities and potential revenue growth for Enanta.
Agios Pharmaceuticals (AGIO) Shares Surge 18.6% Following FDA Approval of Aqvesme
- FDA Approval: Agios Pharmaceuticals announced that its drug Aqvesme received FDA approval, becoming the only treatment for non-transfusion-dependent and transfusion-dependent alpha or beta-thalassemia, which is expected to significantly enhance its market competitiveness.
- Stock Price Rebound: Following the FDA approval announcement, AGIO's stock surged 18.6% to $29.17, with trading volume exceeding average levels, indicating strong investor confidence in the company's prospects.
- Earnings Outlook: Although the upcoming quarterly report is expected to show a loss of $1.96 per share, a 12.6% year-over-year decline, revenues are projected at $11.14 million, reflecting a 3.8% increase from the previous year, demonstrating resilience amid challenges.
- Market Attention: AGIO's consensus EPS estimate has remained unchanged over the past 30 days, and despite the stock's rise, investors should monitor future earnings estimate revisions to assess whether the stock can maintain its upward momentum.
JP Morgan Begins Coverage of Enanta Pharmaceuticals (ENTA) with Positive Outlook
JP Morgan Coverage Initiation: On November 14, 2025, JP Morgan began coverage of Enanta Pharmaceuticals (NasdaqGS:ENTA) with an "Overweight" recommendation, projecting a 62.04% upside based on an average one-year price target of $19.53/share.
Projected Revenue and EPS: Enanta Pharmaceuticals is expected to see a significant increase in annual revenue, projected at $834 million, which represents a 1,186.29% growth, alongside a projected non-GAAP EPS of 10.27.
Institutional Ownership Trends: There are currently 275 funds reporting positions in Enanta Pharmaceuticals, with a slight increase in ownership and a total of 20,591K shares held by institutions, reflecting a 1.16% rise over the last three months.
Shareholder Activity: Notable changes in shareholder positions include Janus Henderson Group increasing its stake by 111.20%, while Millennium Management reduced its holdings by 53.85%, indicating varied strategies among institutional investors.
Enanta Shares Climb Following J.P. Morgan's Overweight Rating on RSV Treatment
Stock Performance: Enanta Pharmaceuticals' shares rose after J.P. Morgan initiated coverage with an Overweight rating, highlighting the potential of their experimental RSV therapy, zelicapavir.
Analyst Projections: Analyst Anupam Rama set a price target of $17 per share, forecasting over $1.5 billion in peak global sales for zelicapavir, with significant contributions expected from the U.S. market.
Clinical Trial Success: The stock's surge followed positive mid-stage trial results for zelicapavir, which is designed for high-risk outpatient adults with acute RSV, indicating strong market potential.
Partnership Opportunities: Enanta is likely to seek partnerships for zelicapavir, which could lead to substantial non-dilutive financing, with peak net global revenue estimates exceeding $300 million.
Enanta Pharmaceuticals Unveils Latest Findings on Zelicapavir and EDP-323, Its N-Protein and L-Protein Inhibitors for Respiratory Syncytial Virus (RSV) Treatment, at IDWeek™ 2025
Zelicapavir's Efficacy in Pediatric Patients: New data presented at IDWeek™ 2025 indicates that zelicapavir significantly shortens the duration of RSV symptoms in children aged 28 days to 36 months, with a median resolution time of 6.99 days compared to 8.60 days for placebo.
EDP-323's Potential in Prophylaxis: EDP-323 has shown high effectiveness in preventing RSV infection when administered post-exposure, with a study revealing that none of the participants receiving EDP-323 became infected, compared to 26% in the placebo group.
Enanta Pharmaceuticals Completes Stock Offering
Public Offering Closure: Enanta Pharmaceuticals has successfully closed its public offering of approximately 7.48 million shares.
Financial Implications: The completion of this offering may impact the company's financial position and future growth strategies.
